A cell surface 230 kDa protein from murine melanoma involved with tumor malignancy.

[1]  J. Berzofsky,et al.  Synergistic Enhancement of CD8+ T Cell–Mediated Tumor Vaccine Efficacy by an Anti–Transforming Growth Factor-β Monoclonal Antibody , 2009, Clinical Cancer Research.

[2]  V. D’Almeida,et al.  Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. , 2007, Neoplasia.

[3]  V. D’Hondt,et al.  Novel treatment strategies for malignant melanoma: a new beginning? , 2007, Critical reviews in oncology/hematology.

[4]  Drew M. Pardoll,et al.  Immunostimulatory monoclonal antibodies for cancer therapy , 2007, Nature Reviews Cancer.

[5]  A. Takaoka,et al.  Comparing antibody and small-molecule therapies for cancer , 2006, Nature Reviews Cancer.

[6]  J. Kirkwood,et al.  Strategies for the Development of More Effective Adjuvant Therapy of Melanoma: Current and Future Explorations of Antibodies, Cytokines, Vaccines, and Combinations , 2006, Clinical Cancer Research.

[7]  R. Chammas,et al.  Melanocyte transformation associated with substrate adhesion impediment. , 2006, Neoplasia.

[8]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[9]  Ya-jun Guo,et al.  The monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma , 2006, BMC Cancer.

[10]  W. Goessler,et al.  Plasmapheresis reverses all side-effects of a cisplatin overdose – a case report and treatment recommendation , 2006, BMC Cancer.

[11]  S. Agarwala,et al.  Cutaneous melanoma: available therapy for metastatic disease , 2006, Dermatologic therapy.

[12]  K. Rock,et al.  Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. , 2005, Cancer research.

[13]  S. Agarwala,et al.  Novel agents in development for the treatment of melanoma , 2005, Expert opinion on investigational drugs.

[14]  L. Travassos,et al.  Transient inflammatory response induced by apoptotic cells is an important mediator of melanoma cell engraftment and growth , 2005, International journal of cancer.

[15]  P. Khavari,et al.  Melanoma genetics and the development of rational therapeutics. , 2005, The Journal of clinical investigation.

[16]  H. Pehamberger,et al.  Vaccination with a Human High Molecular Weight Melanoma-Associated Antigen Mimotope Induces a Humoral Response Inhibiting Melanoma Cell Growth In Vitro1 , 2005, The Journal of Immunology.

[17]  K. Uematsu,et al.  An Anti-Wnt-2 Monoclonal Antibody Induces Apoptosis in Malignant Melanoma Cells and Inhibits Tumor Growth , 2004, Cancer Research.

[18]  H. Kaufman,et al.  Immunotherapy for melanoma. , 2004, Clinics in dermatology.

[19]  A. Heimberger,et al.  A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  F. D. Nascimento,et al.  Enzyme and integrin expression by high and low metastatic melanoma cell lines , 2003, Melanoma research.

[21]  Suyun Huang,et al.  Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. , 2002, Cancer research.

[22]  M. Herlyn,et al.  Cellular and Molecular Biology of Human Melanoma , 2002, Cancer biology & therapy.

[23]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[24]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Bérard,et al.  A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype. , 2000, Cancer research.

[26]  M. Herlyn,et al.  Molecular biology of human melanoma development and progression , 1998, Molecular carcinogenesis.

[27]  Y. Nishinaka,et al.  Development of a human monoclonal antibody to ganglioside G(M2) with potential for cancer treatment. , 1996, Cancer research.

[28]  Gernot Rassner,et al.  Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients , 1995, Cancer.

[29]  D. Elder,et al.  Isolation and functional characterization of the A32 melanoma-associated antigen. , 1994, Cancer research.

[30]  S. Meri,et al.  Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells , 1994, European journal of immunology.

[31]  J. M. Lin,et al.  Subtractive immunization yields monoclonal antibodies that specifically inhibit metastasis , 1993, The Journal of cell biology.

[32]  J. Price,et al.  Phenotypic diversity of murine B16 melanoma detected by anti-B16 monoclonal antibodies. , 1987, Cancer research.

[33]  I. Hellstrom,et al.  Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[35]  G. Poste,et al.  Comparison of the metastatic properties of B16 melanoma clones isolated from cultured cell lines, subcutaneous tumors, and individual lung metastases. , 1982, Cancer research.

[36]  L. Old,et al.  GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody , 1982, The Journal of experimental medicine.

[37]  K. Sikora,et al.  Monoclonal antibodies in oncology , 1982, Journal of clinical pathology.

[38]  I. Fidler,et al.  Tumor heterogeneity and the biology of cancer invasion and metastasis. , 1978, Cancer research.

[39]  M. Herlyn,et al.  Study of antibodies against human melanoma produced by somatic cell hybrids. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[41]  I. Fidler,et al.  Selection of successive tumour lines for metastasis. , 1973, Nature: New biology.

[42]  D. Reintgen,et al.  Immunotherapy for melanoma. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[43]  R. Dummer,et al.  New perspectives on immunobiology and immunotherapy of melanoma. , 1999, Immunology today.

[44]  J. Becker,et al.  Lymphocyte-melanoma interaction: role of surface molecules. , 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.